



# Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.5	09.04.2021	22138-00017	Date of first issue: 15.10.2014

# SECTION 1: Identification of the substance/mixture and of the company/undertaking

### 1.1 Product identifier

Trade name : Human Chorionic Gonadotropin Formulation

# 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

### 1.3 Details of the supplier of the safety data sheet

Company	:	Organon & Co. 30 Hudson Street, 33nd floor 07302 Jersey City, New Jersey, U.S.A
Telephone	:	551-430-6000
E-mail address of person responsible for the SDS	:	EHSSTEWARD@organon.com

# 1.4 Emergency telephone number

215-631-6999

2.2

# **SECTION 2: Hazards identification**

# 2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)						
Reproductive toxicity, Cate	gory	A H360Fd: May damage fertility. Suspect aging the unborn child.	ed of dam-			
Specific target organ toxicit exposure, Category 1	ty - re		gh pro-			
Label elements						
Labelling (REGULATION Hazard pictograms	(EC) :	No 1272/2008)				
Signal word	:	Danger				
Hazard statements	:	H360Fd May damage fertility. Suspected of the unborn child. H372 Causes damage to organs through prolong	0 0			

Precautionary statements

Prevention:

2

peated exposure.

P201 Obtain special instructions before use.



# Human Chorionic Gonadotropin Formulation

Version 3.5	Revision Date: 09.04.2021	SDS Number: 22138-00017	Date of last issue: 25.09.2020 Date of first issue: 15.10.2014	

P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

### Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Hazardous components which must be listed on the label: Gonadotropin, chorionic

# 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

# **SECTION 3: Composition/information on ingredients**

# 3.2 Mixtures

# Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Gonadotropin, chorionic	9002-61-3 232-660-2	Repr. 1A; H360Fd STOT RE 1; H372 (Ovary) specific concentra- tion limit Repr. 1A; H360Fd >= 0,01 % STOT RE 1; H372 >= 0,01 %	>= 90 - <= 100

For explanation of abbreviations see section 16.

according to Regulation (EC) No. 1907/2006



# Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.5	09.04.2021	22138-00017	Date of first issue: 15.10.2014

# **SECTION 4: First aid measures**

4.1 Description of first aid meas	sures
General advice	<ul> <li>In the case of accident or if you feel unwell, seek medical advice immediately.</li> <li>When symptoms persist or in all cases of doubt seek medical advice.</li> </ul>
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	<ul> <li>In case of contact, immediately flush skin with soap and plenty of water.</li> <li>Remove contaminated clothing and shoes.</li> <li>Get medical attention.</li> <li>Wash clothing before reuse.</li> <li>Thoroughly clean shoes before reuse.</li> </ul>
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
4.2 Most important symptoms a	and effects, both acute and delayed
Risks	<ul> <li>May damage fertility. Suspected of damaging the unborn child.</li> <li>Causes damage to organs through prolonged or repeated exposure.</li> </ul>
	Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
4.3 Indication of any immediate	e medical attention and special treatment needed
Treatment	: Treat symptomatically and supportively.
SECTION 5: Firefighting mea	asures

# 5.1 Extinguishing media

Suitable extinguishing media	:	Water spray
		Alcohol-resistant foam
		Carbon dioxide (CO2)
		Dry chemical



# Human Chorionic Gonadotropin Formulation

Versi 3.5	ion	Revision Date: 09.04.2021		)S Number: 138-00017	Date of last issue: 25.09.2020 Date of first issue: 15.10.2014
Unsuitable extinguishing media		:	None known.		
5.2 S	Special	hazards arising from	the	e substance or mi	xture
	Specific hazards during fire- fighting		:	concentrations, and potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a losion hazard. oustion products may be a hazard to health.
	Hazardous combustion prod- ucts		:	Carbon oxides Nitrogen oxides (I Sulphur oxides	NOx)
5.3 A	dvice	for firefighters			
	Special protective equipment for firefighters		:		e, wear self-contained breathing apparatus. tective equipment.
	Specific ods	c extinguishing meth-	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do

# **SECTION 6:** Accidental release measures

# 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment.
	-	Follow safe handling advice (see section 7) and personal pro-
		tective equipment recommendations (see section 8).

# 6.2 Environmental precautions

Environmental precautions	<ul> <li>Avoid release to the environment.</li> <li>Prevent further leakage or spillage if safe to do so.</li> <li>Retain and dispose of contaminated wash water.</li> <li>Local authorities should be advised if significant spillages cannot be contained.</li> </ul>
	0 1 0

# 6.3 Methods and material for containment and cleaning up

Methods for cleaning up	:	Sweep up or vacuum up spillage and collect in suitable con- tainer for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfac- es, as these may form an explosive mixture if they are re- leased into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-
		employed in the cleanup of releases. You will need to deter- mine which regulations are applicable.



# Human Chorionic Gonadotropin Formulation

Version 3.5	Revision Date: 09.04.2021	SDS Number:Date of last issue: 25.09.202022138-00017Date of first issue: 15.10.2014
		Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
See sections	<b>ce to other sections</b> s: 7, 8, 11, 12 and 13.	
SECTION	7: Handling and st	orage
7.1 Precaut	ions for safe handlir	g
Technic	al measures	<ul> <li>Static electricity may accumulate and ignite suspended dust causing an explosion.</li> <li>Provide adequate precautions, such as electrical grounding</li> </ul>
Local/T	otal ventilation	<ul> <li>and bonding, or inert atmospheres.</li> <li>If sufficient ventilation is unavailable, use with local exhaust ventilation.</li> </ul>
	on safe handling	<ul> <li>Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.</li> <li>If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.</li> </ul>
7.2 Conditio	ons for safe storage.	including any incompatibilities
Require	ements for storage nd containers	: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
Advice	on common storage	: Do not store with the following product types: Strong oxidizing agents Organic peroxides Explosives Gases
72 Speaifie	and upp(c)	
7.3 Specific Specific	. ,	: No data available

according to Regulation (EC) No. 1907/2006



# Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.5	09.04.2021	22138-00017	Date of first issue: 15.10.2014

# **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Gonadotropin, chorionic	9002-61-3	TWA	OEB 4 (3 µg/m3)	Internal
		Wipe limit	25 μg/100 cm <sup>2</sup>	Internal

### 8.2 Exposure controls

### **Engineering measures**

Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

If sufficient ventilation is unavailable, use with local exhaust ventilation.

### Personal protective equipment

Eye protection :	Wear the following personal protective equipment: Safety goggles Equipment should conform to NS EN 166
Hand protection	
Material :	Chemical-resistant gloves
Remarks :	Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous sub- stance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
Skin and body protection :	Select appropriate protective clothing based on chemical re- sistance data and an assessment of the local exposure poten- tial. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).
Respiratory protection :	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to NS EN 143
Filter type :	Particulates type (P)

# **SECTION 9: Physical and chemical properties**

# 9.1 Information on basic physical and chemical properties

Physical state

: powder



# Human Chorionic Gonadotropin Formulation

Version 3.5	Revision Date: 09.04.2021		S Number: 38-00017	Date of last issue: 25.09.2020 Date of first issue: 15.10.2014
Oc	lour Iour Iour Threshold	:	off-white odourless No data available	9
Me	Iting point/freezing point	:	No data available	9
	tial boiling point and boiling	:	No data available	9
	nge ammability (solid, gas)	:	May form explos dling or other me	ive dust-air mixture during processing, han- ans.
Fla	mmability (liquids)	:	No data available	9
	per explosion limit / Upper mmability limit	:	No data available	9
	wer explosion limit / Lower mmability limit	:	No data available	9
Fla	ish point	:	Not applicable	
Au	to-ignition temperature	:	No data available	9
De	composition temperature Decomposition tempera- ture	:	No data available	9
рH		:	No data available	9
Vis	cosity Viscosity, kinematic	:	No data available	9
So	lubility(ies) Water solubility	:	soluble	
	rtition coefficient: n- anol/water	:	No data available	9
	pour pressure	:	No data available	9
Re	lative density	:	No data available	9
Re	lative vapour density	:	No data available	9
Pa	rticle characteristics Particle size	:	No data available	2
	er information			
Ex	plosives	:	Not explosive	
Ox	idizing properties	:	The substance o	r mixture is not classified as oxidizing.
Ev	aporation rate	:	No data available	9
Мс	lecular weight	:	No data available	9

according to Regulation (EC) No. 1907/2006



# Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.5	09.04.2021	22138-00017	Date of first issue: 15.10.2014

# **SECTION 10: Stability and reactivity**

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions	<ul> <li>May form explosive dust-air mixture during processing, han- dling or other means.</li> <li>Can react with strong oxidizing agents.</li> </ul>	
10.4 Conditions to avoid		
Conditions to avoid	: Heat, flames and sparks.	

Avoid dust formation.

### 10.5 Incompatible materials

Materials to avoid	: Oxidizing agents
--------------------	--------------------

### **10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

# **SECTION 11: Toxicological information**

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of	:	Inhalation
exposure		Skin contact
		Ingestion
		Eye contact

# Acute toxicity

Not classified based on available information.

## Skin corrosion/irritation

Not classified based on available information.

### Serious eye damage/eye irritation

Not classified based on available information.

### Respiratory or skin sensitisation

### Skin sensitisation

Not classified based on available information.

### **Respiratory sensitisation**

Not classified based on available information.

### Germ cell mutagenicity

Not classified based on available information.

according to Regulation (EC) No. 1907/2006



# Human Chorionic Gonadotropin Formulation

Version 3.5	Revision Date: 09.04.2021		DS Number: 2138-00017	Date of last issue: 25.09.2020 Date of first issue: 15.10.2014
Not o <b>Rep</b> i May	cinogenicity classified based on availa roductive toxicity damage fertility. Suspec uponents:			born child.
	adotropin, chorionic: cts on fertility	:		: Intravenous injection 8,89 mg/kg body weight
				: Intraperitoneal injection 0,883 mg/kg body weight
			Test Type: Fertilit Species: Monkey Fertility: LOAEL: ( Result: Effects on	, 2,224 mg/kg body weight
Effeo men	cts on foetal develop- t	:	Species: Hamster Application Route	: Intraperitoneal injection icity: LOAEL: 60 mg/kg body weight
•	roductive toxicity - As- ment	:	fertility from huma	of adverse effects on sexual function and an epidemiological studies., Some evidence s on development, based on animal experi-

# STOT - single exposure

Not classified based on available information.

## STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.


# Components:

# Gonadotropin, chorionic:

Target Organs Assessment	Ovary Causes damage to organs through prolonged or repeated
	exposure.

# Aspiration toxicity

Not classified based on available information.





# Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.5	09.04.2021	22138-00017	Date of first issue: 15.10.2014

# 11.2 Information on other hazards

# Endocrine disrupting properties

# Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

# Experience with human exposure

# **Components:**

Gonadotropin, chorionic:

Inhalation

Target Organs: ovaries Symptoms: effects on menstruation, gynecomastia, Headache, mental depression, Irritability, restlessness, Fatigue

# **SECTION 12: Ecological information**

# 12.1 Toxicity

No data available

# 12.2 Persistence and degradability

No data available

# 12.3 Bioaccumulative potential

No data available

# 12.4 Mobility in soil

No data available

# 12.5 Results of PBT and vPvB assessment

# Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

# 12.6 Other adverse effects

# Product:

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

according to Regulation (EC) No. 1907/2006



# Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.5	09.04.2021	22138-00017	Date of first issue: 15.10.2014

# **SECTION 13: Disposal considerations**

# 13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations.
	According to the European Waste Catalogue, Waste Codes
	are not product specific, but application specific.
	Waste codes should be assigned by the user, preferably in
	discussion with the waste disposal authorities.
Contaminated packaging	<ul> <li>Empty containers should be taken to an approved waste han- dling site for recycling or disposal.</li> <li>If not otherwise specified: Dispose of as unused product.</li> </ul>
	in not otherwise specified. Dispose of as unused product.

# **SECTION 14: Transport information**

## 14.1 UN number or ID number

Not regulated as a dangerous good

### 14.2 UN proper shipping name

Not regulated as a dangerous good

### 14.3 Transport hazard class(es)

Not regulated as a dangerous good

### 14.4 Packing group

Not regulated as a dangerous good

# 14.5 Environmental hazards

Not regulated as a dangerous good

# 14.6 Special precautions for user

Not applicable

# 14.7 Maritime transport in bulk according to IMO instruments

Remarks

: Not applicable for product as supplied.

# **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII)	:	Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
Regulation (EC) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable



# Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.5	09.04.2021	22138-00017	Date of first issue: 15.10.2014

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

# Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Young people under the age of 18 are not allowed to use or be exposed to the product professionally. Young people above the age of 15 are, however, except from this rule if the product is a necessary part of their education.

### The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

# 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

# **SECTION 16: Other information**

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements		
H360Fd	:	May damage fertility. Suspected of damaging the unborn child.
H372		Causes damage to organs through prolonged or repeated exposure.
Full text of other abbreviations		

Repr.	:	Reproductive toxicity
STOT RE	:	Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule: ENCS - Existing and New Chemical Substances (Japan): ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a



# Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.5	09.04.2021	22138-00017	Date of first issue: 15.10.2014

test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA -Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Classification of the mixture:	Classification procedure:
Sources of key data used to	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data	eChem Portal search results and European Chemicals Agen-
Sheet	cy, http://echa.europa.eu/

Classification of the mixtur	Classification procedure	
Repr. 1A	H360Fd	Calculation method
STOT RE 1	H372	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN